US4808312A - Cellulose ester hollow fiber membrane for plasma separation - Google Patents
Cellulose ester hollow fiber membrane for plasma separation Download PDFInfo
- Publication number
 - US4808312A US4808312A US06/900,584 US90058486A US4808312A US 4808312 A US4808312 A US 4808312A US 90058486 A US90058486 A US 90058486A US 4808312 A US4808312 A US 4808312A
 - Authority
 - US
 - United States
 - Prior art keywords
 - membrane
 - hollow fiber
 - plasma
 - fiber membrane
 - cellulose ester
 - Prior art date
 - Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
 - Expired - Lifetime
 
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 114
 - 239000012510 hollow fiber Substances 0.000 title claims abstract description 44
 - 229920002678 cellulose Polymers 0.000 title claims abstract description 13
 - 238000000926 separation method Methods 0.000 title claims description 36
 - XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
 - 238000007873 sieving Methods 0.000 claims abstract description 13
 - 238000000108 ultra-filtration Methods 0.000 claims abstract description 12
 - 239000011800 void material Substances 0.000 claims abstract description 12
 - 102000007330 LDL Lipoproteins Human genes 0.000 claims abstract description 8
 - 108010007622 LDL Lipoproteins Proteins 0.000 claims abstract description 8
 - 239000011148 porous material Substances 0.000 claims description 18
 - 238000009826 distribution Methods 0.000 claims description 4
 - 238000000746 purification Methods 0.000 abstract description 4
 - 239000000463 material Substances 0.000 abstract description 2
 - 238000002203 pretreatment Methods 0.000 abstract description 2
 - 238000005345 coagulation Methods 0.000 description 22
 - 230000015271 coagulation Effects 0.000 description 22
 - 239000000243 solution Substances 0.000 description 22
 - 102000001690 Factor VIII Human genes 0.000 description 14
 - 108010054218 Factor VIII Proteins 0.000 description 14
 - 229960000301 factor viii Drugs 0.000 description 14
 - 239000008280 blood Substances 0.000 description 12
 - 210000004369 blood Anatomy 0.000 description 12
 - 239000002904 solvent Substances 0.000 description 12
 - 230000035699 permeability Effects 0.000 description 11
 - SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 9
 - 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 8
 - 239000000126 substance Substances 0.000 description 8
 - 238000001125 extrusion Methods 0.000 description 7
 - 238000009987 spinning Methods 0.000 description 7
 - 239000007864 aqueous solution Substances 0.000 description 6
 - 239000000706 filtrate Substances 0.000 description 5
 - 239000007788 liquid Substances 0.000 description 5
 - QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 5
 - 229910052753 mercury Inorganic materials 0.000 description 5
 - 230000001954 sterilising effect Effects 0.000 description 5
 - 238000004659 sterilization and disinfection Methods 0.000 description 5
 - 229920002284 Cellulose triacetate Polymers 0.000 description 4
 - NNLVGZFZQQXQNW-ADJNRHBOSA-N [(2r,3r,4s,5r,6s)-4,5-diacetyloxy-3-[(2s,3r,4s,5r,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6s)-4,5,6-triacetyloxy-2-(acetyloxymethyl)oxan-3-yl]oxyoxan-2-yl]methyl acetate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](OC(C)=O)[C@H]1OC(C)=O)O[C@H]1[C@@H]([C@@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](COC(C)=O)O1)OC(C)=O)COC(=O)C)[C@@H]1[C@@H](COC(C)=O)O[C@@H](OC(C)=O)[C@H](OC(C)=O)[C@H]1OC(C)=O NNLVGZFZQQXQNW-ADJNRHBOSA-N 0.000 description 4
 - 229920000642 polymer Polymers 0.000 description 4
 - 238000002360 preparation method Methods 0.000 description 4
 - LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
 - OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
 - ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
 - FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
 - 230000003247 decreasing effect Effects 0.000 description 3
 - 201000010099 disease Diseases 0.000 description 3
 - 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
 - 230000000977 initiatory effect Effects 0.000 description 3
 - 238000002347 injection Methods 0.000 description 3
 - 239000007924 injection Substances 0.000 description 3
 - 238000000034 method Methods 0.000 description 3
 - 239000011859 microparticle Substances 0.000 description 3
 - 239000002798 polar solvent Substances 0.000 description 3
 - 241000283690 Bos taurus Species 0.000 description 2
 - IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
 - LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
 - WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
 - PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
 - 239000002202 Polyethylene glycol Substances 0.000 description 2
 - HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
 - 238000007598 dipping method Methods 0.000 description 2
 - 239000000835 fiber Substances 0.000 description 2
 - 238000010438 heat treatment Methods 0.000 description 2
 - 239000004816 latex Substances 0.000 description 2
 - 229920000126 latex Polymers 0.000 description 2
 - 238000005259 measurement Methods 0.000 description 2
 - 238000001471 micro-filtration Methods 0.000 description 2
 - 229920001223 polyethylene glycol Polymers 0.000 description 2
 - 230000001105 regulatory effect Effects 0.000 description 2
 - 239000012488 sample solution Substances 0.000 description 2
 - 238000003860 storage Methods 0.000 description 2
 - 238000012360 testing method Methods 0.000 description 2
 - IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
 - 229920008347 Cellulose acetate propionate Polymers 0.000 description 1
 - 229920001747 Cellulose diacetate Polymers 0.000 description 1
 - DQEFEBPAPFSJLV-UHFFFAOYSA-N Cellulose propionate Chemical compound CCC(=O)OCC1OC(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C1OC1C(OC(=O)CC)C(OC(=O)CC)C(OC(=O)CC)C(COC(=O)CC)O1 DQEFEBPAPFSJLV-UHFFFAOYSA-N 0.000 description 1
 - IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
 - FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
 - 101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
 - 239000000853 adhesive Substances 0.000 description 1
 - 230000001070 adhesive effect Effects 0.000 description 1
 - 150000001298 alcohols Chemical class 0.000 description 1
 - 235000013405 beer Nutrition 0.000 description 1
 - 239000010836 blood and blood product Substances 0.000 description 1
 - 239000012503 blood component Substances 0.000 description 1
 - 229940125691 blood product Drugs 0.000 description 1
 - 238000009835 boiling Methods 0.000 description 1
 - 229920001727 cellulose butyrate Polymers 0.000 description 1
 - 229920006218 cellulose propionate Polymers 0.000 description 1
 - 239000003795 chemical substances by application Substances 0.000 description 1
 - 235000012000 cholesterol Nutrition 0.000 description 1
 - 238000004737 colorimetric analysis Methods 0.000 description 1
 - 238000009295 crossflow filtration Methods 0.000 description 1
 - 230000007547 defect Effects 0.000 description 1
 - 238000010612 desalination reaction Methods 0.000 description 1
 - LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
 - 238000005516 engineering process Methods 0.000 description 1
 - 238000002474 experimental method Methods 0.000 description 1
 - 230000002349 favourable effect Effects 0.000 description 1
 - 238000001914 filtration Methods 0.000 description 1
 - 230000005251 gamma ray Effects 0.000 description 1
 - 235000011187 glycerol Nutrition 0.000 description 1
 - 238000005534 hematocrit Methods 0.000 description 1
 - 238000011835 investigation Methods 0.000 description 1
 - 238000004519 manufacturing process Methods 0.000 description 1
 - 238000002156 mixing Methods 0.000 description 1
 - 239000000203 mixture Substances 0.000 description 1
 - 239000012466 permeate Substances 0.000 description 1
 - 239000002953 phosphate buffered saline Substances 0.000 description 1
 - 229920001451 polypropylene glycol Polymers 0.000 description 1
 - 239000000047 product Substances 0.000 description 1
 - 238000010926 purge Methods 0.000 description 1
 - 239000013535 sea water Substances 0.000 description 1
 - 101150035983 str1 gene Proteins 0.000 description 1
 - 238000006467 substitution reaction Methods 0.000 description 1
 - 150000005846 sugar alcohols Polymers 0.000 description 1
 - ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
 - 229910021642 ultra pure water Inorganic materials 0.000 description 1
 - 239000012498 ultrapure water Substances 0.000 description 1
 
Images
Classifications
- 
        
- D—TEXTILES; PAPER
 - D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
 - D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
 - D01D5/00—Formation of filaments, threads, or the like
 - D01D5/24—Formation of filaments, threads, or the like with a hollow structure; Spinnerette packs therefor
 
 - 
        
- B—PERFORMING OPERATIONS; TRANSPORTING
 - B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
 - B01D—SEPARATION
 - B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
 - B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
 
 - 
        
- B—PERFORMING OPERATIONS; TRANSPORTING
 - B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
 - B01D—SEPARATION
 - B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
 - B01D69/08—Hollow fibre membranes
 
 - 
        
- B—PERFORMING OPERATIONS; TRANSPORTING
 - B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
 - B01D—SEPARATION
 - B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
 - B01D71/06—Organic material
 - B01D71/08—Polysaccharides
 - B01D71/12—Cellulose derivatives
 - B01D71/14—Esters of organic acids
 
 - 
        
- D—TEXTILES; PAPER
 - D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
 - D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
 - D01F2/00—Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof
 - D01F2/24—Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof from cellulose derivatives
 - D01F2/28—Monocomponent artificial filaments or the like of cellulose or cellulose derivatives; Manufacture thereof from cellulose derivatives from organic cellulose esters or ethers, e.g. cellulose acetate
 
 
Definitions
- This invention relates to a cellulose ester hollow fiber membrane suitable for the separation of plasma from blood. More particularly, it relates to a hollow fiber membrane made of a cellulose ester which is suitable for the medical use, such as the exchange of plasma in patients, collection of plasma from healthy donors, the pre-treatment of plasma for the collection and purification of valuable materials contained in plasma, and the like.
 - the hollow fiber membrane can be made compact in the volume with keeping the broad area of membrane and can be used in a cross-flow filtration system, and hence, it has widely been used, for instance, in micro filtration, ultrafiltration, in industrial uses such as desalination of sea water or brackish water and ultra-pure water production, and further in medical usage such as purification of blood.
 - a membrane suitable for microfiltration which is used not only in industrial use such as purification of water in the field of foodstuff, and sterilization of draft beer or wine packed in bottle, but also in medical fields, such as for plasma exchange membrane in patients, and for collection of plasma which is necessary for meeting the increased demand of blood products.
 - the membrane used is required to be able to separate stably the plasma within a very short period of time in order to collect the plasma from healthy donors with little load and pain, and further it is required to have high permeabilities of substances having a large molecular weight like in the case of treatment of diseases.
 - the main object of the donorplasmapheresis is to collect Factor VIII having a large molecular weight which is necessary for the treatment of hemophiliac, and hence, it is the most important that the membrane has a high permeability of the Factor VIII.
 - membrane suitable for plasma separation many investigations have been done as to membrane suitable for plasma separation, but available membranes are not satisfactory in view of the stability in the plasma separation rate for the treatment of diseases and also for the collection of plasma and further not satisfactory in the permeability of large molecular weight substances (e.g. Factor VIII, immune complex, etc.).
 - large molecular weight substances e.g. Factor VIII, immune complex, etc.
 - a plasma separation module assembled with the plasma separation membrane is to be sterilized.
 - the sterilization is usually carried out by treatment with EOG (ethylene oxide gas), formalin, or ⁇ -ray, or in an autoclave, but in view of efficiency without any residue of the treating agent, the autoclave sterilization is favorable.
 - EOG ethylene oxide gas
 - formalin formalin
 - ⁇ -ray ethylene oxide gas
 - the autoclave sterilization is favorable.
 - the membrane is deformed because of less heat stability and the membrane properties can not be maintained.
 - the present inventors have intensively studied as to an improved plasma separation membrane having no defect as mentioned above and have found that by using a cellulose ester hollow fiber having a specific range of membrane thickness, a specific correlation between the void volume of the membrane and the ultrafiltration rate, a sieving coefficient of ⁇ -lipoprotein and a specific thermal change ratio, there can be obtained the desired membrane which can be sterilized in an autoclave and has stable plasma separation rate suitable for both medical treatment and collection of plasma and further has improved permeability of large molecular weight substances.
 - FIG. 1 shows a flow sheet for the measurement of a sieving coefficient of ⁇ -lipoprotein, wherein each symbol means as follows:
 - 1 ⁇ -lipoprotein solution
 - 2 a pump for supplying a liquid
 - 3 a heat exchanger
 - 4 a pressure indicator
 - 5 a liquid storage vessel
 - 6 a module
 - 7 a pressure indicator
 - 8 a liquid storage vessel
 - 9 a screw cock
 - 10 a saline solution
 - 11 a pump for sending a liquid
 - 12 a three necked cock.
 - the hollow fiber membrane made of a cellulose ester used in this invention has a membrane thickness of not more than 75 ⁇ m, and has a void volume (x, % by volume) of the membrane and a ultrafiltration rate (y, ml/m 2 .hr.mmHg) satisfying the following formula:
 - Such a hollow fiber membrane can be sterilized in an autoclave and can stably keep the high plasma separation rate for a long period of time and further has improved permeability of large molecular weight substances, such as immune complex and Factor VIII.
 - the ultrafiltration rate (y) When the ultrafiltration rate (y) is over "48x +600" in the above formula, the pores of the hollow fiber membrane are adhered with blood components, particularly with red cells, during the usage of the apparatus, and hence, the plasma separation rate is unfavorably decreased with lapse of time.
 - the rate (y) is less than "55x-2500"
 - undesirable plugging of pores by the large molecular weight substances is increased with the time of treatment, and thereby the plasma separation rate is unfavorably decreased with lapse of time, too.
 - the ⁇ -lipoprotein sieving coefficient (sc) when the ⁇ -lipoprotein sieving coefficient (sc) is less than 0.95, it shows insufficient permeability of the large molecular weight substances such as immune complex and Factor VIII, and hence the membrane is not suitable for the medical treatment and for the collection of plasma.
 - the hollow fiber membrane has a membrane thickness of more than 75 ⁇ m, undesirable plugging of pores is induced at the first stage of the treatment, and hence, the plasma separation rate is unfavorably fixed at a low level.
 - the ratio of change in the axial direction and in the radial direction is controlled so as to be less than 2 %, when the plasma separation module assembled with the hollow fiber membrane is dipped in water at 121° C. for 20 minutes at the state that the both ends of the membrane are free. This means that the membrane can be sterilized in an autoclave at the state that the both ends are fixed.
 - the rate of change is over 2 %, the inner diameter is distributed in the axial direction and further the membrane thickness is distributed in the radial direction during the sterilization in an autoclave, and hence, the membrane properties are unfavorably deteriorated.
 - Suitable cellulose esters used for the preparation of the hollow fiber membrane of the present invention include cellulose diacetate, cellulose triacetate, cellulose propionate, cellulose butyrate, cellulose acetate propionate and the like, which may be used alone or in combination of two or more thereof.
 - the hollow fiber membrane for plasma separation of the present invention can be prepared in the following manner.
 - a spinning solution is prepared by dissolving a polymer (i.e. a cellulose ester) in an aprotic polar solvent or mixing it in a non-solvent in a concentration of 20 % by weight or more.
 - the spinning solution and an inner solution are extruded through a tube in orifice nozzle and then coagulated under the following conditions, so that the pore size of membrane is controlled.
 - Coagulation conditions O ⁇ T 1 -T 2 ⁇ 40 (°C.) wherein T 1 is an extrusion temperature, and T 2 is a temperature of the coagulation bath; and the concentration of the solvent or non-solvent in the coagulation bath and inner solution is >50% by weight.
 - the polymer is dissolved or mixed in an aprotic polar solvent having a boiling point of not lower than 150° C. or in a non-solvent in a polymer concentration of 20% by weight or more.
 - the aprotic polar solvent includes N-methylpyrrolidone (b.p. 202° C.), dimethylformamide (b.p. 153° C.), dimethylacetamide (b.p. 164° C.), dimethylsulfoxide (b.p.
 - the non-solvent includes polyhydric alcohols which are soluble in water, such as ethylene glycol, triethylene glycol, polyethylene glycol, glycerin, polypropylene glycol, etc.; alcohols such as methanol, ethanol, etc.; and water, but should not be limited thereto.
 - the spinning solution as prepared above is subjected to defoaming, heat treatment and filtration, and then extruded through a tube in orifice nozzle. During the extrusion, it is important to supply simultaneously an inner solution within the hollow center of the fiber.
 - the inner solution is a water-soluble coagulation liquid which is usually an aqueous solution of the above-mentioned solvent and non-solvent in a concentration of the solvent or nonsolvent of 50% by weight or more.
 - the resulting hollow fibers are coagulated in a coagulation bath containing an aqueous solution of the above-mentioned solvent or non-solvent.
 - a coagulation bath containing an aqueous solution of the above-mentioned solvent or non-solvent.
 - the temperature of the coagulation bath (T 2 ) at the coagulation step and the extrusion temperature of the tube in orifice nozzle (T 1 ) are regulated to satisfy the correlation of O ⁇ T 1 -T 2 ⁇ 40 (°C.). That is, when there is no difference in the temperature of "T 1 -T 2 " the hollow fibers can not sufficiently be coagulated and hence the membrane pores are not formed, but on the other hand, when the temperature difference "T 1 -T 2 " is over 40° C., the coagulation rate in the forming of pores of membrane becomes too high like the above, and hence, the desired membrane properties can not be obtained.
 - the hollow fiber membrane thus formed is subsequently washed with water and wound up.
 - the hollow fiber membrane is further subjected to heat treatment at 80° C. or higher, preferably to the treatment under the sterilization conditions in an autoclave, i.e. at 115° C. for 30 minutes, at 121° C. for 20 minutes, or at 126° C. for 15 minutes.
 - ⁇ -lipoprotein ( ⁇ -Lipo) sieving coefficient (sc) is measured in the following manner.
 - ⁇ -Lipo (Cohn Fraction III-O, manufactured by United States Biochemical Corporation, Cleveland, Ohio 44128) is dissolved in a phosphate buffered saline in a concentration of 30 mg/dl, and the solution is used in the following method.
 - the starting point of the measurement is the time when the regulation of pressure is finished. Maintaining the pressure at 50 mmHg for 15 minutes, the filtrate from the module 6 is collected for 2 minutes. Simultaneously, the solution to be supplied to the module and the solution passed through the module are sampled at the inlet and the outlet, respectively. The concentrations of the ⁇ -Lipo in the filtrate, the inlet sample solution and the outlet sample solution are measured by a colorimetry, and the value thus obtained is designated as ⁇ a ⁇ , ⁇ b ⁇ , and ⁇ c ⁇ , respectively.
 - the ⁇ -Lipo sieving coefficient (sc) is calculated by the following equation using these value a, b and c:
 - the ultrafiltration rate (y) can be obtained by measuring the unit pressure, unit area, an amount of water permeated per unit time.
 - the cellulose ester hollow fiber membrane as prepared above has excellent properties as mentioned hereinbefore, and has also the following specific structure of membrane.
 - the plasma separation membrane of this invention has a structure containing a large size of pores and an average pore size (p) of the pores distributed in whole membrane walls and the standard deviation of the distribution ( ⁇ ) satisfying the following formulae:
 - the structure of the surface active layer can be observed by an electron microscope.
 - the pore distribution can be measured by a conventional mercury injection method. That is, according to the mercury injection method, the correlation of the injection pressure and the amount of mercury injected can be obtained, and further there can be calculated the pore size from the pressure and the number of pores from the amount of the injected mercury, and the void volume of membrane can also be calculated from the total amount of the injected mercury.
 - Cellulose triacetate (25%), N-methylpyrrolidone (52.5%) and polyethylene glycol (molecular weight: 400, hereinafter referred to as "PEG 400", 22.5%) are mixed to prepared a spinning solution.
 - the solution is extruded through a tube in orifice nozzle together with an inner solution [an aqueous solution of N-methylpyrrolidone (49%) and PEG 400 (21%)] and then introduced into a coagulation bath, wherein the extrusion temperature is 85° C. and the temperature of the coagulation bath is 75° C.
 - the coagulation bath contains an aqueous solution of N-methylpyrrolidone (45.5%) and PEG 400 (19.5%).
 - the membrane is heat-treated at 121° C. for 20 minutes.
 - the hollow fiber membrane thus obtained has the properties as shown in Table 1.
 - the hollow fiber membrane obtained above has a thermal change ratio (i.e. ratio of change after dipping freely in water at 121° C. for 20 minutes) as shown below.
 - Example 1 is repeated except that the temperature of the coagulation bath (75° C.) is changed to 70° C., and there is obtained a hollow fiber membrane.
 - the membrane has the properties as shown in Table 2.
 - Example 1 is repeated except that the concentration of cellulose triacetate in the spinning solution (25%) is changed to 20%, and there is obtained a hollow fiber membrane.
 - the membrane has the properties as shown in Table 3.
 - Example 3 is repeated except that the temperature of the coagulation bath (75° C.) is changed to 65° C., and there is obtained a hollow fiber membrane.
 - the membrane has the properties as shown in Table 4.
 - Example 1 is repeated except that the temperature of the coagulation bath (75° C.) is lowered to 40° C., and there is obtained a hollow fiber membrane.
 - the membrane has the properties as shown in Table 5.
 - the membrane obtained in Reference Example 1 shows inferior plasma separation rate to that of the product of the present invention, that is, it is decreased with lapse of time.
 - Hollow fiber membranes are prepared under the conditions as shown in Table 6, and the properties of the membranes are also shown therein.
 - Cellulose triacetate (26%), N-methylpyrrolidone (51.8%) and PEG 400 (22.2%) are mixed to prepare a spinning solution.
 - the solution is extruded through a tube in orifice nozzle together with an inner solution [an aqueous solution of N-methylpyrrolidone (49%) and PEG 400 (21%)] and then introduced into a coagulation bath, wherein the extrusion temperature is 85° C. and the temperature of the coagulation bath is 70° C.
 - the coagulation bath contains an aqueous solution of N-methylpyrrolidone (45%) and PEG 400 (19.3%).
 - the membrane is heat-treated at 121° C. for 20 minutes.
 - the hollow fiber membrane thus contained has the following membrane structure.
 - Example 5 is repeated except that the polymer concentration is 15% and the temperature of the coagulation bath is 40° C., and there is obtained a hollow fiber membrane.
 - the membrane has the following membrane structure.
 - the hollow fiber membranes prepared in Example 5 and Reference Example 9 were subjected to the test for collection of plasma from blood. That is, bovine blood was passed through the membrane, and the change of properties with lapse of time was measured by checking the sieving coefficient (SC) of total cholesterol at two points of 15 minutes and 30 minutes after the initiation of membrane collection. Besides, the permeability of microparticles was also evaluated by measuring sieving coefficient with Dow Uniform Latex 380 ⁇ , in order to check the permeability of the membranes. The results are shown in Table 7.
 - the follow fiber membrane of this invention did not show any lowering of the plasma separation rate with lapse of time, but on the other hand, that of the reference example showed significant lowering of the rate with lapse of time.
 - the membrane of this invention showed higher permeability of microparticles than that of the membrane of the reference example.
 - the hollow fiber membrane of the reference example has a broad distribution of pores in whole area of the membrane, and hence the microparticles are trapped within the membrane, and thereby the permeability becomes lower.
 
Landscapes
- Chemical & Material Sciences (AREA)
 - Chemical Kinetics & Catalysis (AREA)
 - Engineering & Computer Science (AREA)
 - Textile Engineering (AREA)
 - Mechanical Engineering (AREA)
 - General Chemical & Material Sciences (AREA)
 - Separation Using Semi-Permeable Membranes (AREA)
 - Artificial Filaments (AREA)
 - External Artificial Organs (AREA)
 
Abstract
55x-2500≦y≦48x+600
Description
55-2500≦y≦48x+600
sc=2a/(b+c)
0.01 μm≦p≦0.6 μm, and σ/p≦1.0.
              TABLE 1                                                     
______________________________________                                    
Ultrafiltration rate (ml/m.sup.2 · hr · mmHg)           
                          3,020                                           
Void volume (%)           65                                              
Thickness of membrane (μm)                                             
                          49                                              
sc of β-Lipo         0.96                                            
Initial plasma separation rate (ml/min · mmHg)*                  
                          1.33                                            
SC of Factor VlII***      0.98                                            
Plasma separation rate after 30 min                                       
                          1.17                                            
(ml/min · mmHg)**                                                
SC of Factor VIII***      0.96                                            
______________________________________                                    
 *It means a flow amount of filtered plasma 5 minutes after initiation of 
 supplying of a blood [hematocrit (Ht) 40%] in a flow rate of 50 ml/min in
 a membrane module having an area of 0.25 m.sup.2.                        
 **It means a flow amount of filtered plasma 30 minutes after the         
 initiation of supplying of a blood [Ht 40%] in a flow rate of 50 ml/min i
 a membrane module having an area of 0.25 m.sup.2.                        
 ***The sieving coefficient (SC) is shown by the ratio of the concentratio
 of plasma (C.sub.in) in the initial blood before passing through the     
 membrane to the concentraticn of plasma (C.sub.f) in the filtrate, i.e. S
 = C.sub.f /C.sub.in.                                                     
    
    ______________________________________                                    
Change ratio in the axial direction (%)                                   
                        0.9                                               
Change ratio in the radial direction (%)                                  
                        1.0                                               
______________________________________                                    
 [Note]                                                                   
 The change ratio is measured by dipping a hollow fiber membrane having a 
 length (L) and a membrane thickness (d) in water at 121° C. for 20
 minutes and thereafter measuring the length (L') and membrane thickness  
 (d') of the thustreated hollow fiber membrane and calculating from the   
 following formulae:                                                      
 ##STR1##                                                                 
 ##STR2##                                                                 
    
                  TABLE 2                                                     
______________________________________                                    
Ultrafiltration rate (ml/m.sup.2 · hr · mmHg)           
                           1,600                                          
Void volume (%)            65                                             
Thickness of membrane (μm)                                             
                           65.4                                           
sc of β-Lipo          0.96                                           
Initial plasma separation rate (ml/min · mmHg)                   
                           1.08                                           
SC of Factor VIII          0.97                                           
Plasma separation rate after 30 min (ml/min ·                    
                           1.01                                           
mmHg)                                                                     
SC of Factor VIII          0.95                                           
______________________________________                                    
    
                  TABLE 3                                                     
______________________________________                                    
Ultrafiltration rate (ml/m.sup.2 · hr · mmHg)           
                           4,000                                          
Void volume (%)            76                                             
Thickness of membrane (μm)                                             
                           72.0                                           
sc of β-Lipo          0.95                                           
Initial plasma separation rate (ml/min · mmHg)                   
                           1.58                                           
SC of Factor VIII          0.93                                           
Plasma separation rate after 30 min (ml/min ·                    
                           1.41                                           
mmHg)                                                                     
SC of Factor VIII          0.90                                           
______________________________________                                    
    
                  TABLE 4                                                     
______________________________________                                    
Ultrafiltration rate (ml/m.sup.2 · hr · mmHg)           
                           2,100                                          
Void volume (%)            76                                             
Thickness of membrane (μm)                                             
                           70                                             
sc of β-Lipo          0.95                                           
Initial plasma separation rate (ml/min · mmHg)                   
                           1.21                                           
SC of Factor VlII          0.92                                           
Plasma separation rate after 30 min (ml/min ·                    
                           1.11                                           
mmHg)                                                                     
SC of Factor VIII          0.92                                           
______________________________________                                    
    
                  TABLE 5                                                     
______________________________________                                    
Ultrafiltration rate (ml/m.sup.2 · hr · mmHg)           
                           1,020                                          
Void volume (%)            67                                             
Thickness of membrane (μm)                                             
                           56                                             
sc of β-Lipo          0.72                                           
Initial plasma separation rate (ml/min · mmHg)                   
                           1.12                                           
SC of Factor VIII          0.61                                           
Plasma separation rate after 30 min (ml/min ·                    
                           0.58                                           
mmHg)                                                                     
SC of Factor VIII          0.40                                           
______________________________________                                    
    
                                      TABLE 6                                 
__________________________________________________________________________
                     Thick-    Initial   Plasma                           
Ref.                 ness of   plasma                                     
                                     SC of                                
                                         separation                       
Ex.                  membrane                                             
                           sc of                                          
                               separation                                 
                                     Factor                               
                                         rate after                       
No.                                                                       
   Preparation conditions                                                 
                y  x (μm)                                              
                           β-Lipo                                    
                               rate  VIII                                 
                                         30 minutes                       
__________________________________________________________________________
2  The temp. of coagulation                                               
                1650                                                      
                   78                                                     
                     72.5  0.96                                           
                               0.52  0.90                                 
                                         0.30                             
   bath is further lowered                                                
   20° C. than Example 4                                           
3  The thickness of                                                       
                3600                                                      
                   65                                                     
                     80.3  0.95                                           
                               0.40  0.92                                 
                                         0.38                             
   membrane is set to                                                     
   80.3 μm                                                             
4  The thickness of                                                       
                2150                                                      
                   78                                                     
                     85    0.96                                           
                               0.41  0.92                                 
                                         0.37                             
   membrane is set to                                                     
   85 μm                                                               
5  The composition of                                                     
                3650                                                      
                   65                                                     
                     64.9  0.86                                           
                               0.52  0.79                                 
                                         0.47                             
   coagualation bath in                                                   
   Example 1 is changed                                                   
   as follows:                                                            
   N--methylpyrrolidone/                                                  
   PEG 400 = 25%/20%                                                      
6  The compostion of                                                      
                2200                                                      
                   78                                                     
                     72.1  0.81                                           
                               0.53  0.77                                 
                                         0.49                             
   coagulation bath in                                                    
   Example 4 is changed                                                   
   as follows:                                                            
   N--methylpyrrolidone/                                                  
   PEG 400 = 25%/15%                                                      
__________________________________________________________________________
    
                  TABLE 7                                                     
______________________________________                                    
Collection of plasma from                                                 
                       SC measured with                                   
bovine blood (SC value)                                                   
                       Uniform Latex                                      
Ex. No. 15 min     30 min      380Å                                   
______________________________________                                    
Ex. 5   0.95       0.94        0.89                                       
Ref.    0.72       0.60        0.74                                       
Ex. 7                                                                     
______________________________________                                    
 [Note]: The sieving efficient (SC) is shown by the ratio of the          
 concentration of plasma (C.sub.in) in the initial blood before passing   
 through the membrane to the concentration of plasma (C.sub.f) in the     
 filtrate, i.e. SC = C.sub.f /C.sub. in.   [Note]: The sieving efficient  
 (SC) is shown by the ratio of the concentration of plasma (C.sub.in) in
 the initial blood before passing through the membrane to the concentration
 of plasma (C.sub.f) in the filtrate, i.e. SC=C.sub.f /C.sub.in.
    
    Claims (3)
55x-2500≦y≦48x+600
0.01 μm≦p≦0.6 μm, and σ/p≦1.0.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title | 
|---|---|---|---|
| JP61-134035 | 1986-06-10 | ||
| JP61134035A JPH0653164B2 (en) | 1986-06-10 | 1986-06-10 | Cellulose ester type hollow fiber plasma separation membrane | 
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| US07/239,686 Division US4886631A (en) | 1986-06-10 | 1988-09-02 | Cellulose ester hollow fiber membrane for plasma separation | 
Publications (1)
| Publication Number | Publication Date | 
|---|---|
| US4808312A true US4808312A (en) | 1989-02-28 | 
Family
ID=15118843
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| US06/900,584 Expired - Lifetime US4808312A (en) | 1986-06-10 | 1986-08-26 | Cellulose ester hollow fiber membrane for plasma separation | 
| US07/239,686 Expired - Lifetime US4886631A (en) | 1986-06-10 | 1988-09-02 | Cellulose ester hollow fiber membrane for plasma separation | 
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date | 
|---|---|---|---|
| US07/239,686 Expired - Lifetime US4886631A (en) | 1986-06-10 | 1988-09-02 | Cellulose ester hollow fiber membrane for plasma separation | 
Country Status (4)
| Country | Link | 
|---|---|
| US (2) | US4808312A (en) | 
| JP (1) | JPH0653164B2 (en) | 
| DE (1) | DE3629925C2 (en) | 
| GB (1) | GB2192149B (en) | 
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US5387345A (en) * | 1992-05-20 | 1995-02-07 | Akzo Nv | Cellulose acetate membranes | 
| US6632366B1 (en) * | 1999-05-31 | 2003-10-14 | Daicel Chemical Industries, Ltd. | Cellulose compound hollow fiber membrane | 
| US20030211634A1 (en) * | 2001-09-10 | 2003-11-13 | Jeremy Jerome | Method for adding an apparent non-signal line to a lateral flow assay | 
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US5033005A (en) * | 1988-09-06 | 1991-07-16 | Schlumberger Technologies, Inc. | Analytical computer-aided machining system and method | 
| US5849189A (en) * | 1994-03-08 | 1998-12-15 | Teijin Limited | Hollow fiber blood purifying membrane and process for its production | 
| CA2202969C (en) * | 1996-04-19 | 2001-07-24 | Shingo Emi | Selectively permeable hollow fiber membrane and process for producing same | 
| EP1040396B1 (en) * | 1997-12-22 | 2002-11-06 | StarragHeckert AG | Method for processing work pieces by removing material | 
| DE19910012C1 (en) * | 1999-03-08 | 2001-01-18 | Ostthueringische Materialpruef | Process for the production of molded articles | 
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US4234431A (en) * | 1975-02-15 | 1980-11-18 | Asahi Kasei Kogyo Kabushiki Kaisha | Membrane filtration type hollow fibers and method for the preparation of same | 
| US4459210A (en) * | 1981-05-19 | 1984-07-10 | Teijin Limited | Porous membrane | 
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US4340481A (en) * | 1975-02-15 | 1982-07-20 | Asahi Kasei Kogyo Kabushiki | Membrane filtration type hollow fibers | 
| JPS546916A (en) * | 1977-06-20 | 1979-01-19 | Asahi Chem Ind Co Ltd | Hollow cellulose fibers and their production | 
| JPS5411322A (en) * | 1977-06-29 | 1979-01-27 | Asahi Chem Ind Co Ltd | Hollow cellulose fibers and their production | 
| JPS5584412A (en) * | 1978-12-20 | 1980-06-25 | Nippon Zeon Co Ltd | Production of hollow fiber | 
| CA1153171A (en) * | 1979-12-17 | 1983-09-06 | David T. Chen | Cellulose semipermeable hollow fibers and method for making same | 
| US4681713A (en) * | 1984-03-15 | 1987-07-21 | Toyo Boseki Kabushiki Kaisha | Method of making a hollow fiber membrane for dialysis | 
| US4587168A (en) * | 1984-04-05 | 1986-05-06 | Toyo Boseki Kabushiki Kaisha | Hollow fiber membrane for dialysis | 
- 
        1986
        
- 1986-06-10 JP JP61134035A patent/JPH0653164B2/en not_active Expired - Lifetime
 - 1986-08-26 US US06/900,584 patent/US4808312A/en not_active Expired - Lifetime
 - 1986-08-29 GB GB8620913A patent/GB2192149B/en not_active Expired
 - 1986-09-03 DE DE3629925A patent/DE3629925C2/en not_active Expired - Lifetime
 
 - 
        1988
        
- 1988-09-02 US US07/239,686 patent/US4886631A/en not_active Expired - Lifetime
 
 
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US4234431A (en) * | 1975-02-15 | 1980-11-18 | Asahi Kasei Kogyo Kabushiki Kaisha | Membrane filtration type hollow fibers and method for the preparation of same | 
| US4459210A (en) * | 1981-05-19 | 1984-07-10 | Teijin Limited | Porous membrane | 
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title | 
|---|---|---|---|---|
| US5387345A (en) * | 1992-05-20 | 1995-02-07 | Akzo Nv | Cellulose acetate membranes | 
| US5505890A (en) * | 1992-05-20 | 1996-04-09 | Akzo N.V. | Process for manufacturing cellulose acetate membranes | 
| US6632366B1 (en) * | 1999-05-31 | 2003-10-14 | Daicel Chemical Industries, Ltd. | Cellulose compound hollow fiber membrane | 
| US20030211634A1 (en) * | 2001-09-10 | 2003-11-13 | Jeremy Jerome | Method for adding an apparent non-signal line to a lateral flow assay | 
Also Published As
| Publication number | Publication date | 
|---|---|
| JPH0653164B2 (en) | 1994-07-20 | 
| GB8620913D0 (en) | 1986-10-08 | 
| DE3629925A1 (en) | 1987-12-17 | 
| DE3629925C2 (en) | 1995-08-17 | 
| GB2192149B (en) | 1989-12-13 | 
| US4886631A (en) | 1989-12-12 | 
| GB2192149A (en) | 1988-01-06 | 
| JPS62290468A (en) | 1987-12-17 | 
Similar Documents
| Publication | Publication Date | Title | 
|---|---|---|
| US4612119A (en) | Hollow fiber filter medium and process for preparing the same | |
| US5938929A (en) | Polysulfone hollow fiber semipermeable membrane | |
| Pusch et al. | Synthetic membranes—preparation, structure, and application | |
| EP0294737B1 (en) | Polysulfone hollow fiber membrane and process for making the same | |
| US4780205A (en) | Permselective hollow fiber membrane, process for the preparation thereof, method and apparatus for plasma components separation | |
| US4604326A (en) | Porous regenerated cellulose hollow fiber and process for preparation thereof | |
| EP3574986A1 (en) | Membrane for capillary microfiltration | |
| US4808312A (en) | Cellulose ester hollow fiber membrane for plasma separation | |
| EP0801973A1 (en) | Selectively permeable hollow fiber membrane and process for producing same | |
| US6017474A (en) | Highly permeable polyethersulfone hollow fiber membranes for gas separation | |
| US4681713A (en) | Method of making a hollow fiber membrane for dialysis | |
| EP0012630B1 (en) | Process for producing a cellulose acetate-type permselective membrane, permselective membrane thus produced, and use of such membrane in artificial kidney | |
| US4992221A (en) | Asymmetric gas separation membranes having improved strength | |
| EP0850678B1 (en) | Process for producing hollow fiber membrane, hollow fiber membrane, and dialyzer of hollow fiber membrane type | |
| EP0598690A2 (en) | High-flux hollow-fiber membrane with enhanced transport capability and process for making same | |
| Miao et al. | Production of polyethersulfone hollow fiber ultrafiltration membranes. I. effects of water (internal coagulant) flow rate (WFR) and length of air gap (LAG) | |
| US5783124A (en) | Cellulose acetate hemodialysis membrane | |
| EP0824960A1 (en) | Hollow-fiber membrane of polysulfone polymer and process for the production thereof | |
| WO1995024262A1 (en) | Hollow-fiber blood-purifying membrane and process for producing the same | |
| EP0420832A2 (en) | Asymmetric gas separation membranes having improved strength | |
| JPH0211263B2 (en) | ||
| JPS61200805A (en) | Polyether sulfone microporous hollow yarn membrane and its production | |
| JPH05228208A (en) | Cellulose acetate base blood purifying hollow thread membrane and its manufacture | |
| Mustaffar | Development of Asymmetric Polyethersulfone Hollow Fiber Ultrafiltration Membrane For Cyclodextrin Separation | |
| JPH07106303B2 (en) | Hollow fiber type plasma separation membrane and method for producing the same | 
Legal Events
| Date | Code | Title | Description | 
|---|---|---|---|
| AS | Assignment | 
             Owner name: TOYO BOSEKI KABUSHIKI KAISHA, NO. 2-8, DOJIMAHAMA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:SUZUKI, MITSURU;OHNO, MAKOTO;YAMAMOTO, ISAMU;REEL/FRAME:004597/0067 Effective date: 19860819  | 
        |
| STCF | Information on status: patent grant | 
             Free format text: PATENTED CASE  | 
        |
| FEPP | Fee payment procedure | 
             Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY  | 
        |
| FPAY | Fee payment | 
             Year of fee payment: 4  | 
        |
| FPAY | Fee payment | 
             Year of fee payment: 8  | 
        |
| FPAY | Fee payment | 
             Year of fee payment: 12  |